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Introduction
To support their growth, cancer cells recapitulate latent develop-
mental or physiological processes including those important for 
tissue repair, wound healing, and angiogenesis; however, reacti-
vation of these processes is typically carried out in an exaggerated 
and uncoordinated manner. A good example is the co-option and 
subversion of the different phases of wound healing, which has 
long been recognized as a cardinal feature of solid tumors (1). In 
both healing wounds and tumors, fragile and leaky endothelium 
instigates the formation of a fibrin plug that seals the vasculature 
and prevents blood loss. Granulation tissue consisting of platelets 
along with inflammatory cells reinforces the fibrin plug and helps 
to orchestrate the mobilization and activation of (myo)fibroblasts 
that aid in tissue repair and development of new blood vessels that 
provide oxygen and nutrients and remove waste products (2). The 
patterns of gene expression in tumors and healing wounds are 
remarkably similar to the extent that a “wound signature” is rec-
ognized to have prognostic value in predicting poor patient surviv-
al and cancer progression (3, 4). Despite the similarities, there are 
notable differences; for example, endothelial cells (ECs) express 
several unique factors that can distinguish physiological (wound) 
from pathological (tumor) angiogenesis (5).
While wound healing is an acute, self-limiting, and tightly reg-
ulated process, the “tumor wound” is chronic and proceeds with-
out normal feedback mechanisms. For example, new tumor blood 
vessels are dysfunctional and persistently hyperpermeable, lead-
ing to perivascular fibrin(ogen) deposition (1, 6, 7). Fibrinogen that 
escapes leaky tumor vasculature is rapidly converted to an insol-
uble fibrin meshwork that is cross-linked and stabilized by factor 
XIII. Given its abundant and near-ubiquitous presence in solid
tumors, probes that can detect fibrin or fibrin-fibronectin com-
plexes have recently been used in imaging modalities for various 
cancers and their metastases (8). Fibrin forms a provisional scaf-
fold for angiogenesis, it sequesters growth factors such as VEGF 
and TGF-β, and it is degraded by plasmin, a serine protease that is 
In tumors, extravascular fibrin forms provisional scaffolds for endothelial cell (EC) growth and motility during 
angiogenesis. We report that fibrin-mediated angiogenesis was inhibited and tumor growth delayed following postnatal 
deletion of Tgfbr2 in the endothelium of Cdh5-CreERT2 Tgfbr2fl/fl mice (Tgfbr2iECKO mice). ECs from Tgfbr2iECKO mice failed 
to upregulate the fibrinolysis inhibitor plasminogen activator inhibitor 1 (Serpine1, also known as PAI-1), due in part to 
uncoupled TGF-β–mediated suppression of miR-30c. Bypassing TGF-β signaling with vascular tropic nanoparticles that 
deliver miR-30c antagomiRs promoted PAI-1–dependent tumor growth and increased fibrin abundance, whereas miR-
30c mimics inhibited tumor growth and promoted vascular-directed fibrinolysis in vivo. Using single-cell RNA-Seq and 
a NanoString miRNA array, we also found that subtypes of ECs in tumors showed spectrums of Serpine1 and miR-30c 
expression levels, suggesting functional diversity in ECs at the level of individual cells; indeed, fresh EC isolates from lung 
and mammary tumor models had differential abilities to degrade fibrin and launch new vessel sprouts, a finding that was 
linked to their inverse expression patterns of miR-30c and Serpine1 (i.e., miR-30chi Serpine1lo ECs were poorly angiogenic 
and miR-30clo Serpine1hi ECs were highly angiogenic). Thus, by balancing Serpine1 expression in ECs downstream of TGF-β, 
miR-30c functions as a tumor suppressor in the tumor microenvironment through its ability to promote fibrin degradation 
and inhibit blood vessel formation.
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ipated functional diversity in subtypes of ECs in tumors that can 
be attributed to expression patterns of miR-30c and Serpine1 that 
is also associated with clinical outcomes in breast cancer patients. 
Our findings shed light on the specific functional role of TGF-β 
in the tumor vasculature and identify what we believe to be new 
tumor-supportive properties for the highly specialized, aberrant, 
and heterogeneous tumor endothelium (30–32).
Results
Postnatal deletion of Tgfbr2 in endothelium delays tumor growth and 
impairs blood vessel formation. TGF-β plays a well-defined role in 
the promotion of fibrosis, tissue scarring, and wound healing as 
a result of its ability to activate multiple genes important for cell 
motility, survival, and coagulation and hemostasis (33). Howev-
er, the function of TGF-β in pathophysiological processes such as 
tumor growth is challenging to study in a cell-type–specific man-
ner in vivo and requires, for example, conditional deletion strate-
gies using lineage-specific Cre drivers (34). Furthermore, because 
TGF-β is reported to have both pro- and antiangiogenic activities 
in ECs that are dose and context dependent, the precise function 
of TGF-β in the vasculature during tumor growth and progression 
is unclear (35–37). To define the role of TGF-β in the endothelium 
during tumor growth, we generated mice with conditional dele-
tion of Tgfbr2 by crossing Cdh5-CreERT2 mice with Tgfbr2fl/fl mice 
(referred to herein as Tgfbr2iECKO mice) (Figure 1A) (38). As we 
described previously, in some of these mice we also bred in the Ai6 
ZSGreen reporter to facilitate EC isolation, to confirm EC-specific 
Cre activity, and to demonstrate disruption in TGF-β signaling in 
ECs from engrafted tumors (Supplemental Figure 1, A and B; sup-
plemental material available online with this article; https://doi.
org/10.1172/JCI123106DS1) (39). Because Tgfbr2 is required for 
signaling following its dimerization with TGF-βR1, the resultant 
Tgfbr2iECKO mice show disabled TGF-β signaling in the endotheli-
um in response to all 3 TGF-β ligands following tamoxifen admin-
istration. After generating these mice and control mice (also treat-
ed with tamoxifen), we orthotopically engrafted syngeneic EO771 
mammary tumor cells into the mammary fat pad and then mea-
sured tumor volumes daily. The results showed that tumor sizes 
were smaller and tumor volumes were reduced by 1.8-fold (746.7 
± 46.7 cm3 versus 400.2 ± 74.1 cm3) and that tumor weights were 
reduced by 1.6-fold (1.1 ± 0.14 g versus 0.65 ± 0.1 g) in Tgfbr2iECKO 
mice compared with control mice (Figure 1B). CD31 staining for 
blood vessel networks revealed that tumors in Tgfbr2iECKO mice 
had a 2.4-fold reduction in total vascular area along with a 3.1-fold 
reduction in open vessel lumens compared with controls (Figure 1, 
C and D). Furthermore, using an automated software platform to 
analyze vessel branching and complexity, we observed a reduction 
in the total number of vessel branches when normalized to tumor 
area and a reduction in branch length when distributed by fre-
quency in Tgfbr2iECKO tumors versus controls (Figure 1, E and F). In 
H&E-stained paraffin sections, we also observed less amorphous 
pink-colored material, verified to be fibrin(ogen) that had escaped 
leaky vasculature, in tumors from Tgfbr2iECKO mice compared with 
those from control mice (data not shown and Supplemental Fig-
ure 2, A and B). Taken together, these results suggest that TGF-β 
signaling is important for the development of tumor blood vessels 
that support primary mammary tumor growth.
 
generated from the zymogen plasminogen by key components of 
the plasminogen-activating system including tissue plasminogen 
activator (tPA), urokinase plasminogen activator (uPA), and uro-
kinase plasminogen activator receptor (uPAR). Fibrin degradation 
liberates growth factors and generates fibrin degradation products 
that themselves can serve as a serum biomarker to detect tumors 
of various origins.
Inhibition of fibrin degradation is mediated in part by plasmin-
ogen activator inhibitor 1 (Serpine1, also known as PAI-1), which 
binds to and inactivates uPA and tPA causing the internalization of 
uPA via uPAR and LDL receptor–related protein 1 (LRP1) (9). Nota-
bly, PAI-1 is enriched in and actively secreted by the endothelium, 
prompting its designation as “endothelial PAI-1” or “Serpin E1.” 
PAI-1 is overexpressed in multiple cancers, especially breast can-
cer, in which its higher expression predicts worse overall survival, 
development of metastases, and poor responses to chemothera-
py (10). Despite established associations between overexpression 
of PAI-1 and tumor progression, its role in solid tumors remains 
controversial and context dependent. For example, blocking PAI-1 
using pharmacological inhibitors diminishes the growth of most 
tumors, but other tumor types are not affected (9, 11–15). Likewise, 
several studies in PAI-1–KO mice demonstrated growth inhibition 
of engrafted tumors, whereas other studies showed no obvious 
effect (9, 16–20). These opposing outcomes may be related to the 
dose-dependent effects of PAI-1 in different types of cells in the 
tumor microenvironment (TME), local versus systemic inhibition 
of PAI-1 itself, and expression and bioavailability of TGF-β, the 
major transcriptional activator of Serpine1.
The regulation of Serpine1 by TGF-β and its major downstream 
effectors (SMADs) is well characterized (21). Upon TGF-β binding 
of the type 2 receptor, the recruited type 1 receptor phosphory-
lates and thereby activates receptor-associated SMADs (RSMADs) 
such as SMAD2 and SMAD3. These RSMADs form complexes 
with SMAD4 and, in cooperation with additional cofactors, rapid-
ly upregulate Serpine1 mRNA (22, 23). Apart from transcriptional 
regulation of Serpine1 mRNA production by TGF-β, it was recently 
shown that several miRNAs, in particular the miR-30 family, also 
regulate Serpine1 expression by binding directly to its 3′-UTR. In 
a study using human vascular ECs, the upregulation of Serpine1 
by proangiogenic placental growth factor (PLGF) was augmented 
when miR-30c was blocked (24). Moreover, PLGF and TGF-β were 
shown to downregulate miR-30c and miR-30d expression in ECs 
and non-ECs, an event that was linked to several pathological con-
ditions including fibrosis and thrombosis (24–26). While miR-30c 
itself was recently associated with cancer progression (e.g., breast 
cancer), in which it serves as a prognostic biomarker in tumor tissue 
and plasma, no studies have identified a specific role for miR-30c in 
the TME; in particular, the function of miR-30c and its regulation 
by TGF-β in the tumor vasculature are entirely unknown (27–29).
Here, we used mice with targeted disruption of Tgfbr2 in the 
endothelium to explore tumor growth and blood vessel matura-
tion in the absence of TGF-β signaling. By screening the function-
al properties of isolated EC subtypes and their TGF-β responses 
ex vivo, we have identified a vascular-directed pathway, driven 
by an axis between TGF-β, miR-30c, and Serpine1, that links a 
tumor-induced fibrinolytic pathway in the endothelium with 
tumor progression. Furthermore, we have uncovered an unantic-
bona fide EC marker mRNAs, and positive uptake of Dil-Ac-LDL 
along with CD31 (also known as PECAM) expression confirmed 
EC purity (Figure 2, A and B, and Supplemental Figure 3A) (39). 
As expected, Tgfbr2iECKO ECs showed reduced phosphorylated 
SMAD2 (p-SMAD2) upon TGF-β stimulation, confirming that 
TGF-β signaling was disabled (Figure 2C). To assess the in vivo and 
in vitro angiogenic potential of Tgfbr2iECKO ECs versus control ECs, 
we performed fibrin plug assays in syngeneic mice and sprout-
Tgfbr2iECKO ECs show impaired fibrin-mediated angiogenesis in 
vivo and in vitro and fail to upregulate Serpine1 and downregulate 
miR-30 miRNAs. Next, we isolated primary ECs from the lungs 
of Tgfbr2iECKO and WT mice to examine their in vitro responses to 
TGF-β. After preparing several EC isolates from Tgfbr2iECKO mice, 
we performed FACS and quantitative PCR (qPCR) to identify an 
isolate with complete disruption of Tgfbr2 (40). As we have shown 
previously, expression of the ZSGreen reporter, enrichment for 
Figure 1. Postnatal deletion of Tgfbr2 in endothelium delays tumor growth and impairs blood vessel formation. (A) Study design including tamoxifen 
treatment and orthotopic mammary tumor injection schedule for control versus Tgfbr2iECKO mice. (B) Mammary tumors from control mice versus those from 
Tgfbr2iECKO mice. Tumor volumes were determined with calipers using the formula: volume = (length × width2)/2. Final tumor weights are presented in grams 
(control, n = 12; Tgfbr2iECKO, n = 15). *P < 0.05, by  ANOVA with Sidak’s multiple comparisons test (volume) and Student’s t test (weight). (C) CD31 staining of 
control versus Tgfbr2iECKO mammary tumors. The inset images show a representative open or closed lumen of a blood vessel in each tumor. Scale bars: 100 
μm; zoom, ×4 (insets). (D) Percentage of vascular area and number of open lumens per field in tumors from control versus Tgfbr2iECKO mice (n = 5 tumors 
examined per group). *P < 0.05, by Student’s t test. (E) Image analysis scheme to determine branch lengths in tumors from control versus Tgfbr2iECKO mice. 
See Methods for analysis details. The representative vessel is from the far-right inset in C. Scale bar: 100 μm. (F) Quantification of branch lengths in control 
versus Tgfbr2iECKO tumors using the “analyze skeleton” feature in ImageJ Fiji (see Methods for details). Results were determined by Mann-Whitney U test. 
Histogram analysis of branch length shows the number of branches binned per 20-pixel interval (n = 3 tumors per group). Data represent the mean ± SEM.
in vitro, whereas Tgfbr2iECKO ECs were deficient in their ability to 
form new sprouts in fibrin (0.7 ± 0.2 sprouts/bead) (Figure 2, D 
and E). Sprout lengths were 2.7-fold longer at 72 hours in control 
ECs compared with those in ECs from their Tgfbr2iECKO counter-
parts (211.5 ± 11.9 μm versus 78.5 ± 5.9 μm), suggesting that intact 
TGF-β signaling in ECs is required to promote the formation of 
mature vascular structures in a fibrin matrix.
ing assays in fibrin gels (41). By perfusing mice with lectin594 just 
before euthanasia, we could distinguish host-derived (ZSGreen– 
lectin594+) ECs from engrafted (ZSGreen+ lectin594+) ECs. Con-
sistent with what we observed in Tgfbr2iECKO mice, the engrafted 
control ECs formed greater numbers of vessels compared with 
their KO counterparts; furthermore, we found that control ECs 
launched numerous sprouts per bead (6.3 ± 0.3 sprouts/ bead) 
Figure 2. Tgfbr2iECKO ECs show impaired fibrin-mediated angiogenesis in vitro and fail to upregulate Serpine1 and downregulate miR-30 miRNAs. (A) Vali-
dation of EC isolation from ZSGreen reporter mice. Phase and ZSGreen images of isolated ECs.  Scale bar: 10 μm. (B) qPCR analysis of EC and fibroblast genes 
from control and Tgfbr2iECKO mice. Samples were assayed in triplicate. (C) Western blot showing phosphorylated SMAD2 (p-SMAD2) in ECs challenged with 10 
ng/ml TGF-β to confirm disabled Tgfbr2 signaling. (D) In vivo fibrin plugs from control versus Tgfbr2iECKO ECs. Lectin594 was injected prior to euthanasia. Scale 
bar: 100 μm. Phalloidin-stained ECs in the fibrin bead–sprouting assay at 72 hours. Arrows indicate examples of individual sprouts that were quantified. The 
scale at bottom right indicates sprout depth in the 3D fibrin matrix. Scale bars: 40 μm (x) and 54 μm (y). (E) Quantification of the fibrin-sprouting assay over 
time. The number and length of sprouts were measured for each indicated time point (n = 30 beads per time point). (F) qPCR analysis of TGF-β–induced and 
fibrinolysis-regulating genes in control versus Tgfbr2iECKO ECs. Samples were assayed in triplicate. (G) miR-30 family miRNA expression in ECs treated with 10 
ng/ml TGF-β for 48 hours. Samples were assayed in triplicate. (H) Ectopic miR-30c mimic transfection and qPCR analysis of miR-30c levels along with fibrino-
lysis-regulating genes. Samples were assayed in triplicate. *P < 0.05, by ANOVA (E) and Student’s t test (F–H)  Data represent the mean ± SEM. 
revealed that control ECs had reduced fibrin degradation when 
challenged with TGF-β, whereas Tgfbr2iECKO ECs did not (Supple-
mental Figure 3B). Thus, impaired tumor growth and angiogenesis 
in Tgfbr2iECKO mice accompanies a failed induction of Serpine1 (a 
major vascular-enriched inhibitor of plasmin generation and thus 
fibrin degradation) in ECs that is necessary for balancing the rate 
of fibrinolysis and fibrin-mediated vessel maturation in the TME.
Recently, it was suggested that members of the miR-30 family 
of miRNAs target the Serpine1 gene and regulate EC morphogen-
esis (44, 45); however, links between TGF-β, miR-30c, Serpine1, 
Because these in vitro sprouting assays are performed in a 
fibrin-rich microenvironment similar to that found in solid tumors, 
we hypothesized that Tgfbr2iECKO ECs had enhanced fibrinolytic 
activity, resulting in loss of the fibrin scaffolds that are required 
to produce stable vessels (42, 43). By using qPCR to measure the 
expression of TGF-β–induced genes known to control fibrinolysis, 
we found that the fibrinolysis inhibitor Serpine1 was the only gene 
that was increased in control ECs but not in Tgfbr2iECKO ECs after 
TGF-β challenge (Figure 2F). Acta2 and Col1a1 were used as TGF-β–
regulated positive controls. Furthermore, fibrin zymography gels 
Figure 3. miR-30c mimics block Serpine1 expression and inhibit in vitro EC sprouting. (A) Two pathways to Serpine1 induction by TGF-β signaling in ECs. 
(B) qPCR analysis of miR-30c in ECs treated with 10 ng/ml TGF-β, 20 nM miR-30c mimic, or a combination of both. Samples were assayed in triplicate 
(n = 3). (C) qPCR analysis of Serpine1 in ECs treated with 10 ng/ml TGF-β, 20 nM miR-30c mimic, or the combination. Samples were assayed in triplicate 
(n = 3). (D) Western blot analysis of PAI-1 in ECs treated with 10 ng/ml TGF-β, 20 nM miR-30c mimic, or a combination of both. Ponceau staining (PS) was 
used to show equal loading. (E) Fibrin bead–sprouting assay in ECs treated with miR-30c mimic for 72 hours (n = 30 beads). Controls were treated with a 
40-nM scrambled sequence. (F) Number and length of sprouts in ECs treated with miR-30c mimic, rPAI-1 (0.8 μg/ml), or a combination of both for 72 hours 
(n = 30 beads). (G) qPCR analysis of ECs treated with 10 ng/ml TGF-β for each indicated time point. Samples were assayed in triplicate (n = 3). (H) qPCR 
analysis of ECs treated with 10 ng/ml TGF-β, 10 μM α-amanitin, or a combination of both. Samples were assayed in triplicate (n = 3). (I) qPCR analysis of 
pre-miRNA for miR-30c in ECs treated with 10 ng/ml TGF-β for the indicated durations. Samples were assayed in triplicate (n = 3). *P < 0.05, by Student’s 
t test (B and C), ANOVA (E), and Student’s t test (F). Data represent the mean ± SEM.
and fibrin-mediated angiogenesis have not been elucidated. 
Thus, we hypothesized that in addition to the well-characterized 
SMAD-dependent regulation of Serpine1, TGF-β may also reg-
ulate endothelial Serpine1 expression via a miR-30–dependent 
mechanism that controls sprouting angiogenesis. First, we used 
qPCR to measure the levels of miR-30 family members in control 
versus Tgfbr2iECKO ECs in the presence and absence of TGF-β. We 
observed that TGF-β strongly reduced the expression of miR-30 
miRNAs (with the exception of miR-30e) in control ECs but not in 
Tgfbr2iECKO ECs (Figure 2G). Because miR-30c is reported to have 
the highest degree of species conservation with respect to binding 
sites in the 3′-UTR of Serpine1, we turned our attention to miR-
30c for subsequent analysis (24). Ectopic expression of miR-30c 
in both control and Tgfbr2iECKO ECs was sufficient to reduce Ser-
pine1 mRNA expression by 50%, but other well-known fibrinolysis 
genes including uPa, tPa, and uPar were not affected (Figure 2H).
miR-30c mimics block Serpine1 expression and inhibit in vitro EC 
sprouting. Next, we tested whether miR-30c was capable of regulat-
ing TGF-β–induced Serpine1 expression in ECs in parallel to the well-
known SMAD-dependent regulation of Serpine1 (Figure 3A). Ecto-
pic expression of miR-30c was reduced by TGF-β addition and was 
sufficient to abrogate TGF-β–induced Serpine1 (and PAI-1 secretion) 
in ECs (relative to TGF-β–treated controls) (Figure 3, B–D). TGF-β–
mediated reduction in miR-30c was dose dependent, was not simi-
larly regulated by other angiogenic factors including VEGF and basic 
fibroblast growth factor (bFGF), and was independent of SMAD4 (a 
co-SMAD that is typically needed for RSMADs to properly function) 
and Eri-1 (an exoribonuclease suggested to negatively regulate the 
abundance of some mature miRNAs) (Supplemental Figure 4, A–C) 
(33, 46). Ectopic miR-30c expression was also sufficient to dose- 
dependently reduce sprout numbers and length in fibrin-mediated 
angiogenesis assays in vitro, but this effect was rescued by adding 
exogenous recombinant PAI-1 (rPAI-1) (Figure 3, E and F, and Sup-
plemental Figure 5A). As expected, silencing Serpine1 using siRNAs 
phenocopied the effect of the miR-30c mimic, as it reduced sprout 
numbers and length (Supplemental Figure 5, B and C); taken togeth-
er, miR-30c controls Serpine1 expression downstream of TGF-β, and 
an axis between these 3 factors may function as an important “rheo-
stat” for controlling the rate of vascular-directed fibrin generation 
and degradation and vessel morphogenesis.
To begin to understand the mechanism whereby TGF-β might 
regulate miR-30c, we examined the temporal expression patterns 
of miR-30c and Serpine1. We found that the reduction in miR-30c 
by TGF-β generally coincided inversely with the increase in Ser-
pine1, suggesting that miR-30c processing or transcription might 
be affected (Figure 3G). Indeed, miR-30c expression was reduced 
with similar kinetics by the Pol2 inhibitor α-amanitin in both the 
presence and absence of TGF-β (Figure 3H). Using primers specific 
for the miR-30c pre-miRNA coding sequence found within chromo-
some 1, we found that TGF-β resulted in a time-dependent reduc-
tion in the generation of the pre-miRNA for miR-30c, which preced-
ed the reduction in miR-30c transcript expression (Figure 3I). Of 
note, these results do not conflict with the recently described target- 
directed miRNA degradation mechanism whereby Serpine1 mRNA 
can itself control the expression of miR-30c after serum stimulation 
(47). Thus, TGF-β appears to interfere with the transcriptional path-
way that generates mature miR-30c from pre-miRNA precursors.
miR-30c gain of function in the endothelium inhibits tumor growth 
and reduces fibrin abundance, whereas miR-30c loss of function does 
the opposite. To assess the function of miR-30c in tumor-associated 
ECs (TECs) in vivo, we used vascular tropic 7C1 nanoparticles that 
efficiently deliver nucleic acid payloads to the vasculature in tumor 
models (48, 49). We chose the E0771 mammary tumor cell line that 
is low or absent for Serpine1 mRNA expression and PAI-1 secretion, 
even when challenged with TGF-β in vitro (Figure 4, A and B). Thus, 
ECs are probably the predominant source of locally acting PAI-1 
in these tumors in vivo. After injecting EO771 tumor cells orthot-
opically into the mammary fat pad, the mice were treated 3 times 
per week with 7C1 mimic (miR-30c conjugates) or 7C1 scrambled 
nanoparticles. The results showed that tumor volumes were reduced 
by 3.9-fold (308.5 ± 65.3 cm3 versus 78.5 ± 16.5 cm3) and final tumor 
weights by 2.3-fold (0.7 ± 0.2 g versus 0.3 ± 0.08 g) in the 7C1 mimic– 
treated versus 7C1 scramble–treated mice (Figure 4, C and D). 
Using a similar strategy, we tested how miR-30c loss of function in 
the endothelium would impact tumor growth. In contrast to ecto-
pic miR-30c expression, 7C1 antagomiRs (anti–miR-30c) striking-
ly stimulated tumor growth compared with 7C1 scramble–treated 
control mice. We observed a 4.3-fold increase in overall final tumor 
volume (1043.2 ± 162.1 cm3 versus 243.5 ± 32.5 cm3) and a 2.1-fold 
increase in final tumor weight (1.7 ± 0.4 g versus 0.8 ± 0.3 g) in 7C1 
antagomiR–treated compared with 7C1 scramble–treated mice (Fig-
ure 4, C and D). Notably, we observed no significant change in tumor 
volumes in the 7C1 mimic– or 7C1 antagomiR–treated mice versus 
the 7C1 scramble–treated mice on a PAI-1–KO background, suggest-
ing that the impact of miR-30c on tumor growth via the vasculature 
requires host-derived PAI-1 (Figure 4E).
To ensure that ECs were being targeted in these tumors, 
we used FACS to isolate and molecularly profile ZSGreen+ ECs 
from EO771 tumors injected into the mammary fat pads of Cdh5-
CreERT2 ZSGreenfl/fl mice treated with 7C1 mimics or 7C1 antago-
miRs. ZSGreen– “non-ECs” were collected in tandem as a neg-
ative control, and sample purities were confirmed using qPCR 
(Supplemental Figure 6, A and B). We detected a 63% reduction 
in Serpine1 mRNA expression and 5.1-fold increase in miR-30c 
levels in ECs from the 7C1 mimic–treated versus the 7C1 scram-
ble–treated mice. We observed no difference in expression of 
miR-30c or Serpine1 in the non-EC fraction (Figure 4, F and G). 
In contrast, ECs from the 7C1 antagomiR–treated group had a 
7.7-fold increase in Serpine1 mRNA and a 2.7-fold decrease in 
miR-30c expression compared with 7C1 scrambled control ECs. 
Again, we observed no significant change in expression of Ser-
pine1 or miR-30c in the isolated non-ECs (Figure 4, F and G). The 
circulating levels of PAI-1 in plasma measured by ELISA were 
also decreased by 3-fold in the 7C1 mimic–treated mice but were 
increased by approximately 2-fold in the 7C1 antagomiR–treated 
mice compared with the 7C1 scramble–treated mice, indicating 
that ectopic manipulation of miR-30c in the vasculature is suffi-
cient to alter PAI-1 secretion by TECs (Figure 4, H and I).
Characterization of blood vessels using immunohistology 
revealed a 3-fold reduction in vessel area (4.5% ± 0.4 % versus 
1.4% ± 0.2 %) and a 20-fold reduction in intratumoral fibrin (6.2% 
± 1.9 % versus 0.3% ± 0.05%) in 7C1 mimic–treated mice (Figure 
4, J and K). Thus, ectopic expression of miR-30c in the vasculature 
reduced intratumoral fibrin abundance, which was accompanied 
Figure 4. miR-30c gain of function in the endothelium inhibits tumor growth and reduces fibrin abundance, whereas miR-30c loss of function has the opposite 
effect. (A) qPCR analysis in E0771 mammary tumor cells and ECs treated with 10 ng/ml TGF-β for 48 hours. Samples were assayed in triplicate (n = 3). (B) Western 
blot analysis of PAI-1 in E0771 mammary tumor cells or ECs treated with 10 ng/ml TGF-β for 48 hours. PS was used to show equal loading. (C) Tumor volume 
measurements of mice bearing orthotopic E0771 mammary tumors treated intravenously with 1.5 mg/kg 7C1 scrambled versus 1.5 mg/kg 7C1 mimic or 1.5 mg/kg 
7C1 scrambled versus 7C1 antagomiR. Data were combined from 2 independent experiments (n = 10–11 mice/group). (D) Tumor weights in mice treated as in C. Data 
were combined from 2 independent experiments (n = 10–11 mice/group). (E) Tumor volume measurements of PAI-1–KO mice bearing orthotopic E0771 mammary 
tumors treated with 7C1 scrambled, 7C1 mimic, or 7C1 antagomiR (n = 3–4 mice/group). (F) qPCR analysis of Serpine1 expression in FACS-sorted ZSGreen+ ECs and 
ZSGreen– non-ECs from orthotopic E0771 mammary tumors from mice treated with 7C1 scrambled, 7C1 mimic, or 7C1 antagomiR as in C (n = 3 mice/group; n = 2 
replicates). (G) qPCR analysis of miR-30c using FACS-enriched ZSGreen+ ECs and ZSGreen– non-ECs as in F. (H) Plasma PAI-1 levels in mice treated as indicated 
(n = 5 mice/group). (I) Plasma PAI-1 levels in mice treated as indicated (n = 5 mice/group). (J) Immunofluorescence images of E0771 mammary tumors from mice 
treated with 7C1 scrambled, 7C1 mimic, or 7C1 antagomiR, as above. Nuclei were counterstained with DAPI. Scale bar: 100 μm. (K) Quantification of vascular area 
and fibrin deposition area in E0771 mammary tumors from mice treated with 7C1 scrambled, 7C1 mimic, or 7C1 antagomiR (n = 5 tumors/group). *P < 0.05, by 
Student’s t test (A, D, F–I, and K). Data represent the mean ± SEM. 
To assess the relationship between miR-30c and Serpine1 
during EC function in vitro, we simplified the process by desig-
nating EC isolates on the basis of their binary expression patterns 
of miR-30c and Serpine1/PAI-1: miR-30clo Serpine1hi ECs secret-
ed abundant PAI-1 when challenged with TGF-β, whereas miR-
30chi Serpine1lo ECs had much lower PAI-1 secretion (Figure 5E). 
Remarkably, these EC subtypes behaved in an entirely different 
manner in fibrin bead–sprouting assays. For example, miR-30clo 
PAI-1hi ECs had an arborescent appearance in fibrin (producing 4.4 
± 0.19 sprouts/bead over 72 hours), sharply contrasting with their 
miR-30chi PAI-1lo counterparts, which appeared uncoordinated 
and dysmorphic in their sprouting abilities and instead produced 
stunted and immature vascular structures consisting of only 0.1 ± 
0.1 sprouts/bead during the same time period (Figure 5, F and G).
TGF-β dose-dependently stimulated sprouting in both EC 
subtypes (though fewer sprouts were present in miR-30chi PAI-1lo 
ECs overall) and reduced fibrin degradation as determined with 
fibrin zymograms (Supplemental Figure 8B and Supplemental 
Figure 9, A–C). Plating miR-30clo PAI-1hi ECs on fibrin was suffi-
cient to reduce miR-30c and increase Serpine1 mRNA expression, 
but this did not occur in ECs from Tgfbr2iECKO mice (Supplemental 
Figure 9, D and E). Notably, miR-30chi PAI-1lo ECs could be partial-
ly induced to form sprouts in different matrices including collagen 
1 and Matrigel, indicating that their responses to fibrin-mediated 
angiogenesis were selectively impaired (Supplemental Figure 10, 
A and B). These results suggest that the presence of fibrin itself 
elicits Tgfbr2-dependent activation of the fibrinolytic pathway 
in ECs that could be driven by autocrine upregulation of TGF-β 
ligands once ECs encounter fibrin matrices. Taken together, we 
have identified subtypes of ECs in tumors, characterized by a 
reciprocal expression pattern of miR-30c and Serpine1, that show 
differential abilities to degrade fibrin and form new vascular struc-
tures in vitro (Figure 5H).
Identification of Serpine1-enriched TEC subpopulations in vivo 
using single-cell RNA-Seq. Next, using the 10X Genomics droplet- 
based sequencing system, we performed single-cell RNA-Seq 
(scRNA-Seq) of FACS-isolated ZSGreen+ normal mammary endo-
thelial cells (NECs) or TECs to further assess cellular heterogeneity, 
particularly with regard to the distribution of genes important for 
hemostasis and fibrinolysis (Figure 6A). From a total of 2,791 ECs 
sequenced (1,799 NECs and 992 TECs) and using unsupervised 
graph-based clustering followed by principal component analysis 
(PCA) and t-stochastic neighbor embedding (t-SNE), we identi-
fied 11 distinct clusters overall (Figure 6B). We performed differ-
ential expression analysis of TECs versus NECs, followed by gene 
set enrichment analysis (GSEA) (52–55). Of note, compared with 
NECs, TECs showed enrichment for genes with important roles in 
epithelial-mesenchymal transition (EMT), coagulation, and immune 
and inflammatory responses (Figure 6C). Selected candidate genes 
from this analysis are shown in Supplemental Figure 11.
We next reclustered TECs to identify subpopulations on the 
basis of differential expression of selected genes important for 
coagulation and fibrinolysis. Within TEC clusters, we found 5 
subpopulations (shown as populations 0–4 in the t-SNE plot) (Fig-
ure 6D). Interestingly, Serpine1 expression was largely restricted 
to a single TEC cluster (cluster 1). We also found enrichment for 
uPar (which binds urokinase, restricts plasminogen activation, 
by fewer blood vessels and smaller tumors with a pale, avascular 
appearance when viewed by gross morphology (Supplemental 
Figure 7A). In contrast, blood vessel densities and fibrin depo-
sition measurements showed a 1.9-fold increase in vessel area 
(4.7% ± 0.3 % versus 8.7% ± 0.8 %) and a 6.5-fold increase in fibrin 
deposition (7.8% ± 2.6 % versus 50.6% ± 17.1 %) in 7C1 antagomiR–
treated mice (Figure 4, J and K). 7C1 antagomiR–treated tumors 
were superficially bloody in appearance, which is an indicator 
of increased blood vessel density and/or vascular perturbations 
(Supplemental Figure 7B). Taken together, both gain and loss of 
function of miR-30c in ECs using vascular-tropic nanoparticles 
resulted in a predictable impact on several parameters related 
to tumor progression: miR-30c overexpression inhibited tumor 
growth, angiogenesis, and fibrin deposition, while miR-30c antag-
omiRs produced the opposite result.
Heterogeneous TECs show a spectrum of miR-30c and Serpine1 
expression that defines their in vitro sprouting abilities. To further 
explore the specific role of miR-30c and Serpine1 in the TME, we 
used FACS to isolate TECs from 2 orthotopic tumor models or from 
human lung cancer specimens. Using qPCR, we found that miR-30c 
was expressed by TECs in both murine and human tumors; how-
ever, the level of expression varied dramatically between isolates, 
suggesting that there could be functional heterogeneity in subtypes 
of TECs based on their intrinsic expression patterns of miR-30c 
(Figure 5A). To test this possibility and to assess the regulation of 
miR-30c by TGF-β in relation to other putative “angiomiRs,” we 
isolated primary TECs from C3-TAg mammary tumors, a spon-
taneous tumor model we have previously used to retrieve several 
TEC isolates for in vitro culture expansion (39, 50). A NanoString 
miRNA array platform was used to measure the abundance of miR-
30 (and ~600 other miRNAs) in TECs challenged with TGF-β ex 
vivo (Figure 5B). Notably, miR-126 was the most abundant miRNA 
detected, consistent with its designation as an angiomiR that is 
known to be enriched in the endothelium (51). In accordance with 
our previous results, TGF-β stimulation resulted in the downregu-
lation of miR-30a/-b/-c/-d in TEC cultures (Figure 5B). Additional 
miRNAs that were increased or decreased by TGF-β challenge can 
be found in the Supplemental NanoString array data file.
To establish links between the expression of miR-30c and 
functional heterogeneity in the endothelium, we assayed 8 TEC 
isolates by selecting and expanding CD31+CD45– colonies gen-
erated from collagenase-dispersed tumors, as we described pre-
viously (31, 39, 50). Using C3-TAg mouse mammary TECs and 
KRASG12D lung TECs, we again found a spectrum of miR-30c 
expression across different isolates; i.e., some TECs had high miR-
30c expression, whereas others had low expression (Figure 5C). 
As predicted, TGF-β stimulation resulted in a broad range of Ser-
pine1 induction across these different isolates, with high miR-30c 
expressers showing the lowest induction of Serpine1 (Figure 5D). 
The induction of Serpine1 did not appear to relate to the expres-
sion of Tgfbr2 or its coreceptor endoglin, because the expression 
of these factors was not significantly or consistently associated 
with the level of Serpine1 expression induced by TGF-β (data not 
shown). Using Pearson’s correlation analysis, we found an inverse 
relationship between the expression of miR-30c and Serpine1 
mRNA in TECs from both models, further suggestive of an associ-
ation between these 2 factors (Supplemental Figure 8A).
overall. Notably, the enrichment of these different genes was 
not always found within the same TEC clusters, suggesting that 
subpopulations of TECs are differentially specialized in terms of 
their ability to coordinate fibrin generation and degradation. For 
and was previously shown to be expressed in sprouting EC tip 
cells) and Serbp1 (a relatively unexplored factor suggested to play 
a role in Serpine1 mRNA stability) within distinct TEC clusters 
(56). uPA and tPA were expressed at comparatively lower levels 
Figure 5. Heterogeneous tumor–associated ECs show a spectrum of miR-30c and Serpine1 expres-
sion that defines their in vitro sprouting abilities. (A) qPCR analysis of FACS-enriched TECs from 
orthotopic E0771 mammary tumors, orthotopic 344SQ lung tumors, and human lung tumor spec-
imens. Samples were assayed in triplicate (n = 3 tumors). (B) PCA of NanoString array using TECs 
treated with 10 ng/ml TGF-β for 48 hours. A heatmap of miR-30 family members is also shown. (C) 
qPCR analysis of individual isolates of TECs from the indicated murine tumor model. Samples were 
assayed in triplicate (n = 3). (D) qPCR analysis in C3-TAg TECs or KRASG12D TECs treated with 10 ng/
ml TGF-β for 48 hours. Samples were assayed in triplicate. Samples are arranged from low (far left) 
to high (far right) miR-30c expression on the graph (n = 3). (E) Western blot analysis of PAI-1 using 
conditioned media from miR-30clo PAI-1hi and miR-30chi PAI-1lo ECs treated with TGF-β (0, 1, 5, and 
10 ng/ml for 48 hours). PS was used to show equal loading. (F) Images of miR-30clo PAI-1hi and miR-
30chi PAI-1lo ECs in a fibrin-sprouting assay. Arrowheads indicate aberrant sprout formation in miR-
30chi PAI-1lo ECs. The scale at bottom right indicates sprout depth in the 3D fibrin matrix. Scale bar: 
40 μm (x) and 54 μm (y). (G) Number of sprouts and length of sprouts per bead in miR-30clo PAI-1hi 
and miR-30chi PAI-1lo ECs. Sprouts were counted at the indicated time points (n = 30 beads per time 
point). *P < 0.05, by ANOVA. (H) Schematic of TEC subtypes showing angiogenic (miR-30clo PAI-1hi) 
versus dysmorphic (miR-30chi PAI-1lo) TECs identified in this study. Data represent the mean ± SEM.
firming that miR-30c antagomiRs or miR-30c mimics would either 
promote or block PAI-1 secretion, respectively, we tested the direct 
role of miR-30c during sprouting angiogenesis in these EC sub-
types (Figure 7A). Strikingly, we found that blocking miR-30c in 
miR-30chi PAI-1lo ECs was sufficient to partially rescue their aber-
rant sprouting abilities in fibrin, whereas miR-30c mimics reduced 
in vitro sprouting in the miR-30clo Serpine1hi subtype (Figure 7, B 
and C). Notably, these EC subtypes were advantageous for further 
confirming the activity of 7C1 nanoparticles coupled to miR-30c 
mimics or miR-30c antagomiRs, both of which produced sustained 
effects on PAI-1 secretion and in vitro fibrinolysis as determined 
using fibrin zymograms (Supplemental Figure 12, A–D).
example, plotting their expression across the 5 subpopulations or 
plotting Serpine1 by individual cells from selected subpopulations 
showed a broad spectrum of expression (Figure 6, E and F). Thus, 
there are several genes of known importance during the regula-
tion of coagulation and fibrinolysis enriched in TECs, but their 
expression is compartmentalized and highly variable within dis-
tinct cell subpopulations.
The balance between miR-30c and Serpine1 controls vascular- 
directed fibrinolysis and angiogenesis. We next took advantage of 
the EC subtypes uncovered in this study to further explore how a 
miR-30c/Serpine1 axis controls the rate of vascular-directed fibri-
nolysis and tumor-associated blood vessel formation. After con-
Figure 6. Identification of Serpine1-enriched TEC subpopulations in vivo using scRNA-Seq. (A) Experimental design for isolating ZSGreen+ NECs or TECs 
for scRNA-Seq. E0771 mammary tumors or normal mammary glands were harvested (from the contralateral side, n = 3 individual mice), pooled, and sub-
jected to 10X Genomics scRNA-Seq. (B) t-SNE plots showing clustering of NECs versus TECs. (C) GSEA showing hallmark pathways in TECs versus NECs as 
determined from scRNA-Seq data. (D) TEC reclustering and t-SNE plots showing enrichment and expression of 5 coagulation and fibrinolysis genes in TEC 
subpopulations. Serpine1 expression was mostly restricted to population 1. (E) Violin plots showing differential enrichment of Serpine1, uPar, and Serbp1 
across 5 TEC subpopulations. (F) Serpine1 expression by individual cell in TEC subpopulation 1 showing a spectrum of Serpine1.
Figure 7. The balance between miR-30c and Serpine1 controls vascular-directed fibrinolysis and angiogenesis. (A) Western blot for PAI-1 using 
conditioned media from miR-30chi PAI-1lo ECs treated with 20 nM miR-30c antagomiR or miR-30clo PAI-1hi ECs treated with 20 nM miR-30c mimic. 
Cells were treated for the indicated durations before harvesting the culture medium. (B) Representative images of vascular structures (fibrin bead 
assay) in miR-30chi PAI-1lo ECs treated with 20 nM miR-30c antagomiR and in miR-30clo PAI-1hi ECs treated with 20 nM miR-30c mimic. Images were 
captured after 48 hours. The scale at bottom right indicates sprout depth in the 3D fibrin matrix. Scale bars: 40 μm (x) and 54 μm (y). (C) Number of 
sprouts per bead and average sprout length of miR-30chi PAI-1lo ECs treated with 20 nM miR-30c antagomiR and miR-30clo PAI-1hi ECs treated with 
20 nM miR-30c mimic. Sprouts were counted and measured at the indicated time points (n = 30 beads per condition). Results were analyzed using 
ANOVA. (D) Western blot using conditioned media from miR-30chi PAI-1lo ECs treated with the indicated doses of TSB for 48 hours. PS was used to 
show equal loading. (E) qPCR for other miR-30c targets in TSB-treated ECs. Samples were assayed in triplicate. (F) Representative images of vas-
cular structures (fibrin bead assay) in miR-30chi PAI-1lo ECs treated with 20 nM TSB or 20 nM scrambled TSB control. Images were captured after 48 
hours. Arrowhead indicates an EC sprout. Color scale indicates sprout depth in the 3D fibrin matrix. Scale bars: 40 μm (x) and 54 μm (y). (G) Number 
of sprouts per bead and average sprout length in miR-30chi PAI-1lo ECs treated with 20 nM TSB or 20 nM scrambled TSB control (n = 30 beads per 
condition). *P < 0.05, by ANOVA (C and G). Data represent the mean ± SEM.
Ube2i, and Itgb3 (Figure 7, D and E). The TSB also partially res-
cued in vitro sprouting, which was indicated by conversion of an 
immature and poorly organized cellular “sheet” into a more ste-
reotypical pattern of vessel branches that increased in number 
and length over time, as is typical of ECs (Figure 7, F and G).
Because we found that fibrin was reduced in tumors from 
Tgfbr2iECKO mice compared with those from controls, we assayed 
the ability of miR-30c antagomiRs to bypass loss of the TGF-β 
receptor and promote vessel sprouting and fibrin abundance 
(by inhibiting fibrin degradation) in Tgfbr2iECKO ECs. Consistent 
with our previous results above, vessel sprouting was diminished 
miR-30c targets multiple genes that could hypothetically 
influence vessel sprouting via different mechanisms, thus we 
used a target site blocker (TSB) to determine the specific role 
of the miR-30c/Serpine1 axis during fibrin-mediated vessel 
sprouting. Unlike miR-30c antagomiRs that reduce the inter-
action of miR-30c with multiple mRNAs, the TSB should only 
prevent miR-30c from targeting Serpine1, while leaving other 
miR-30c–mRNA interactions intact. Using the miR-30chi PAI-1lo 
EC subtype, we found that a TSB was sufficient to promote PAI-1 
secretion and increase Serpine1 mRNA without increasing the 
expression of other known miR-30c targets including Dll4, 
Figure 8. Concurrent miR-30clo Serpine1hi expression cumulatively predicts decreased patient survival in a large cohort of breast cancer patients. (A) 
METABRIC data were downloaded from the Sage BioNetworks Synapse database (https://www.synapse.org/#!Synapse:syn1688369/wiki/27311). mRNA 
and miRNA expression data and clinical overall survival data from approximately 1285 patients were examined. SERPINE1 expression in a large cohort 
of breast cancer patients from a METRABRIC data set is shown. SERPINE1hi is defined as patients with SERPINE1 expression higher than the median 
SERPINE1 expression level. SERPINE1lo is defined as patients with SERPINE1 expression levels lower than or equal to the median SERPINE1 expression 
level. (B) miR-30c expression in breast cancer patients from the METABRIC data set. Definitions similar to those described above for SERPINE1 were 
used for patients’ miR-30chi and miR-30clo expression levels. (C) Concurrent expression of miR-30c and SERPINE1 in patients with breast cancer from the 
METRABIC data set. SERPINE1lo miR-30chi is defined as patients with SERPINE1 expression lower than the median SERPINE1 expression level and miR-30c 
expression higher than the median miR-30c expression level. SERPINE1hi miR-30clo is defined as patients with SERPINE1 expression higher than the medi-
an SERPINE1 expression level and miR-30c expression lower than the median miR-30c expression level. The remaining patients were defined as “others.” 
(D) SERPINE1 expression across breast cancer subtypes in The Cancer Genome Atlas Breast-Invasive Carcinoma (TCGA-BRCA) data set. TCGA breast cancer 
data were downloaded from the FireBrowse database (http://firebrowse.org/). mRNA and miRNA expression data and PAM50 subtypes were examined. 
(E) miR-30c expression across breast cancer subtypes in the TCGA-BRCA data set.
Discussion
Tumor vasculature, as in wounded vasculature, is typically leaky 
and hyperpermeable, mainly because of the influence of VEGF, 
which leads to the escape of plasma proteins such as fibrinogen 
(57). Although multiple cell types, extracellular matrix (ECM) 
components, and soluble factors contribute to the wound-
healing– like response observed in tumors, seminal observations 
by Dvorak describe the near-ubiquitous presence of fibrin(ogen) 
in solid tumors, and later studies demonstrated that fibrin itself is 
directly proangiogenic (1, 6, 58–60). Biomechanical forces, driv-
en by thickened sheets of cross-linked ECM in tumors, may also 
compress the endothelium, leading to vascular injury and plasma 
leakage (61). The perivascular accumulation of fibrin, along with 
matrix proteins such as fibronectin, provides scaffolds for new 
blood vessels (and for cancer cells) and is suggested to be a princi-
pal instigator of many of the sequential steps that typify the wound 
healing–like response observed in solid tumors (7). Thus, how the 
endothelium senses and responds to the presence of extravascular 
fibrin is important for vessel homeostasis and vessel maturation 
as tumors develop. Given its strong transcriptional regulation of 
the Serpine1 gene, TGF-β is central during the coordination of the 
mainly vascular-driven processes that control the rate of fibrin 
deposition, fibrin degradation, and tumor progression.
In the present study, we hypothesize that an axis between 
TGF-β, miR-30c, and Serpine1 functions as a fibrin-producing 
pathway in ECs. We demonstrate that a balance in the expression 
and regulation of these 3 factors controls fibrin abundance and 
vessel morphogenesis; for example, an imbalance in the expres-
sion of miR-30c results in hyperfibrinolytic vessels that are dys-
morphic and grow chaotically, and this imbalance is rescued by 
ectopic expression of a miR-30c antagomiR or a TSB directed to 
the miR-30c–binding site in the Serpine1 gene. Interestingly, this 
hyperfibrinolytic phenotype resembles virally transduced ECs 
that were shown to have enhanced proteolytic activity and form 
hemangioma- like cystic structures in vitro (62, 63). Upregulated 
protease activity mediated by the uPAR and activation of the TGF-β 
pathway itself in sprouting tip cells have also been described; thus, 
there appear to be subtypes of ECs positioned throughout the 
vasculature that have specialized properties that become import-
ant during vascular-driven fibrinolysis and sprouting angiogene-
sis (56). Our results point to an exaggerated wound-healing–like 
response within these tumor EC subtypes that may relate to selec-
tion pressures driven by conditions in the TME (i.e., chronic EC 
exposure to fibrin and cross-linked ECM) that directly regulate 
miR-30c expression; alternatively, preexisting EC subtypes may 
have different abilities to degrade fibrin and form new vascular 
structures, activities that are related to their intrinsic miR-30c and 
Serpine1 expression levels.
The pathways that regulate the balance between fibrin deposi-
tion and fibrin degradation have long been recognized as import-
ant contributors to tumor progression. Patients with breast can-
cer were shown to have higher levels of circulating D-dimer (a 
fibrin degradation product) compared with levels in patients with 
benign breast disease or carcinoma in situ, indicating an active 
fibrinolytic process in malignant cancers or a systemic activation 
of coagulation pathways (64). Furthermore, patients with breast 
or lung cancer with increased PAI-1 in tumors or in serum have 
in ECs from Tgfbr2iECKO mice; however, addition of the miR-
30c antagomiR was sufficient to promote vessel sprouting in 
vitro (Supplemental Figure 13, A and B). Furthermore, miR-30c 
antago miRs reduced the robust fibrin degradation in Tgfbr2iECKO 
ECs that are ordinarily unresponsive to TGF-β (Supplemental 
Figure 13C). Taken together, our results support the concept that 
(a) subtypes of ECs in tumors can be functionally stratified on
the basis of their expression patterns of miR-30c and Serpine1, 
and (b) miR-30c plays an important role, downstream of TGF-β, 
in balancing fibrin degradation during blood vessel formation.
Concurrent miR-30clo Serpine1hi expression cumulatively predicts 
decreased patient survival in a large cohort of breast cancer patients. 
Finally, because it is challenging to examine the coexpression of 
miR-30c and/or Serpine1 in human tumor–associated blood ves-
sels in situ and then correlate their expression levels with clinical 
sequelae, we instead accessed METABRIC (Molecular Taxonomy 
of Breast Cancer International Consortium) gene expression data 
(https://www.synapse.org/#!Synapse:syn1688369/wiki/27311), 
which includes breast tumor sample and clinical endpoint data 
from approximately 1200 patients with breast cancer. Of note, 
breast cancer cells typically do not express PAI-1, or they express 
very low levels of PAI-1, compared with ECs, as indicated using 
core biopsies from 12 independent breast tumors found in the pub-
licly available Human Protein Atlas (https://www.proteinatlas.org). 
Given the identified role for a Serpine1/miR-30c axis in medi-
ating fibrin degradation in the TME of mice, the reported over-
expression of SERPINE1 in human breast cancer tissues which 
correlates with worse overall survival, and the influence of fibrin- 
fibronectin complexes in breast cancer progression, we hypoth-
esized that breast cancer patients with concurrent SERPINE1hi 
miR-30clo expression patterns would have worse overall survival 
compared with their SERPINE1lo miR-30chi counterparts (8). First, 
we examined survival patterns that might distinguish SERPINE1hi 
versus SERPINE1lo and miR-30chi versus miR-30clo patients with 
breast cancer. We found that patients with either higher SERPINE1 
or lower miR-30c expression had worse overall survival (Figure 8, 
A and B). These results are consistent with the recently reported 
favorable prognostic outcome in a separate cohort of breast cancer 
patients with miR-30chi expression relative to their miR-30clo coun-
terparts (27). Other miR-30 family members did not show a similar 
association (data not shown). Notably, patients with higher SER-
PINE1 expression also had lower miR-30c (r = –0.14, P = 8.744–07, 
data not shown), and patients with concurrent SERPINE1hi and 
miR-30clo coexpression showed a worse survival outcome com-
pared with that of the remaining patients (Figure 8C). Thus, there 
is an improved ability to predict patient outcomes when SERPINE1 
and miR-30c expression are examined concurrently as opposed to 
individually. Finally, we also found that the expression of SERPINE1 
and miR-30c mirror one another and is negatively correlated in dif-
ferent cancer subtypes, with SERPINE1 expression being highest in 
the LumA subtype in parallel with the lowest expression of miR-30c 
(Figure 8, D and E). Taken together, these results are consistent with 
a tumor-suppressive function of miR-30c and a tumor-promoting 
ability of SERPINE1 in the microenvironment of human breast 
cancer. We propose that these effects are due in part to cooperation 
between these factors which mediate the rate of perivascular fibrin 
generation and degradation throughout the TME.
cell lines that express endogenous PAI-1 and in different tumor 
settings in which PAI-1 is operative, including metastatic and 
premetastatic microenvironments (77).
Finally, we have shown that lower expression of miR-30c in 
patients with breast cancer predicts a worse prognosis and con-
firmed that higher expression of SERPINE1 is also a poor prog-
nosis indicator as was previously shown in the European Orga-
nization for Research and Treatment of Cancer – Receptor and 
Biomarker Group (EORTC-RBG) patient cohort (~8,000 breast 
cancer patients) (78). We also show that combining these expres-
sion signatures resulted in a greater cumulative predictive val-
ue relating to overall patient survival. While it is challenging to 
assign this outcome specifically to the differential functions of 
TECs in breast tumors that match this particular genetic signa-
ture, our results are consistent with a tumor-suppressive role for 
miR-30c in human breast cancers overall, which we link to its 
profibrinolytic activity in the TME. Moreover, because SERPINE1 
is known to be highly enriched in ECs, it is likely that SERPINE1 
mRNA expression in these patients’ tumors is largely represented 
by the tumor vasculature or possibly by other stromal cells such 
as fibroblasts. Notably, and in solid agreement with our findings, 
gene expression profiling of microdissected microvasculature 
from human breast tumors showed that SERPINE1, along with 
additional gene clusters, can stratify patients on the basis of EC 
heterogeneity signatures alone (79). Taken together, we have 
identified what to our knowledge is a previously unrecognized 
TGF-β/PAI-1–dependent and miR-30c–regulated pathway that 
coordinates vascular-directed fibrinolysis and blood vessel mor-
phogenesis in tumors. Our work thus demonstrates important 
links between regulation of the fibrinolytic pathway and tumor 
progression and does so by taking into account the heterogeneous 
properties of the tumor endothelium.
Methods
Animals. Tgfbr2fl/fl mice were crossed with Cdh5-CreERT2 to generate 
Tgfbr2iECKO mice. Some mice were further crossed with Ai6 ZSGreen 
reporter mice to facilitate EC isolation. PAI-1 knockout, Ai6 ZsGreen, 
Tgfbr2fl/fl, and C57BL/6 control mice were purchased from The Jack-
son Laboratory at 7 weeks of age. Cdh5-CreERT2 mice were generated 
by Ralf Adams (Max Planck Institute for Molecular Biomedicine). 
LSL-KRASG12D/+ p53fl/fl Lkb1fl/fl mice were provided by Chad Pecot (UNC 
Chapel Hill). C3-TAg mice were provided by the Mouse Phase 1 Unit 
at the Lineberger Comprehensive Cancer Center of the University of 
North Carolina at Chapel Hill.
In vivo animal studies. PAI-1–KO, Cdh5-CreERT2, Ai6 ZSGreen, 
Tgfbr2fl/fl, and control mice were all on a C57BL/6 background. 
C3-TAg mice were on a friend virus B NIH (FVB/N) background. 
LSL-KRASG12D/+ p53fl/fl Lkb1fl/fl mice were on a sv129/s4 background. 
All tumor studies were performed with 8- to 10-week-old mice with a 
mean weight of 18 to 22 g. Age-matched mice, generated from breed-
ing pairs or ordered directly from The Jackson Laboratory, were ran-
domly allocated to each experimental or control group. Tamoxifen 
was used to induce deletion of Tgfbr2 and/or induce expression of 
Cre-controlled genes (e.g., the ZSGreen reporter). Mice at 6 to 7 weeks 
of age were treated 3 times over the course of 7 days with i.p. injec-
tions of 75 mg/kg tamoxifen. The mice were allowed to recover for 1 
week before beginning mammary tumor studies.
 
a worse overall survival and higher incidence of metastasis com-
pared with patients with lower PAI-1 levels (65, 66). However, the 
specific role of PAI-1 during tumor progression, like the presence 
of intratumoral fibrin(ogen) itself, is controversial and context 
dependent, especially with regard to tumor angiogenesis (67–69). 
These discrepancies may relate to the cell type–specific and can-
cer stage–dependent functions of PAI-1 within the TME, or may 
be due to alternative and fibrin-independent roles for PAI-1 in can-
cer cells, including the ability of PAI-1 to protect against apoptosis 
and support cell motility via PAI-1–vitronectin interactions (19, 
70). Thus, to directly assess how influencing EC-mediated fibri-
nolysis via miR-30c–regulated PAI-1 would impact tumor growth, 
we took advantage of vascular tropic nanoparticles, previously 
shown to efficiently target the vasculature, to deliver miR-30c 
mimics or miR-30c antagomiRs into WT versus PAI-1–KO mice 
(48, 49). While we demonstrated a clear effect of ectopic miR-30c 
(or miR-30c antagomiR) on fibrin abundance, vessel morphogen-
esis, and tumor growth, one limitation was that all blood vessels 
were targeted rather than tumor blood vessels specifically; howev-
er, because we affected a pathway that is probably only activated 
in sprouting, leaky neovasculature like that found in tumors, our 
approach is unlikely to impact preexisting vasculature in resting 
tissues (but will likely affect the wound-healing process). Despite 
this limitation, we show that manipulating miR-30c in the tumor 
endothelium phenocopied predicted outcomes related to PAI-1  
expression; for example, high circulating PAI-1 levels driven by 
miR-30c blockade were associated with rapid tumor growth, 
whereas ectopic miR-30c expression was associated with reduced 
PAI-1 and slower tumor growth.
A second limitation relates to the use of PAI-1–KO mice in this 
study. We demonstrate that host PAI-1 was necessary for mediat-
ing a response to targeted delivery of miR-30c mimics or antag-
omiRs but that mammary tumor growth was strongly delayed or 
inhibited on the PAI-1–KO background, making it challenging 
to extend these studies over a prolonged period. This growth 
delay may be related to the almost complete absence of PAI-1 
expression in EO771 tumor cells, indicating that our model sys-
tem is essentially PAI-1 null. It is therefore possible that PAI-1– 
independent effects of miR-30c in the vasculature may appear 
over time as tumors further develop. Indeed, miR-30c and 
other miR-30 family members were shown to target addition-
al factors, including the Notch ligand DLL4, that can influence 
blood vessel sprouting and morphogenesis via different mecha-
nisms (71, 72). The targeting of additional pathways by miR-30c 
in ECs, outside the context of canonical angiogenic signaling, 
is also possible (73, 74). Similarly, plasmin has both fibrin and 
nonfibrin substrates, and while we demonstrated that inhibiting 
PAI-1 expression with miR-30c mimics enhanced plasmin activ-
ity by fibrin zymograms, we cannot rule out the possibility that 
plasmin was exerting a tumor growth–inhibitory effect in our 
model by cleaving additional nonfibrin substrates such as FasL 
and L1Cam (75). Because of its strong upregulation of PAI-1,  
our use of the miR-30c antagomiR could similarly protect ECs 
from FasL-mediated apoptosis, which was previously shown in 
the context of tumor growth (76). In future studies, it will be 
interesting to test our strategy for vascular-tropic, nanoparticle- 
mediated delivery of miR-30c mimics using additional tumor 
length, the level of significance was determined using a nonpara-
metric Mann-Whitney U test. All analyses were performed using 
GraphPad Prism 5 (GraphPad Software). A P value of less than 0.05 
was considered significant. All quantitative data represent the mean 
± SEM from at least 3 or more samples or experiments per data point. 
Additional experimental details (number of animals or cells and 
experimental replications) are provided in the figure legends. All box 
and whisker plots show the minimum and maximum values and a 
horizontal line at the mean.
Study approval. All clinical samples were collected with the patients’ 
consent under a UNC Chapel Hill IRB-approved protocol (IRB no. 
14-1755). All animal experiments were carried out in accordance with 
and under approval of the IACUCs of the University of Virginia and 
the University of North Carolina at Chapel Hill. Both universities are 
accredited by the AAALAC International and follow the Public Health 
Service Policy for the Care and Use of Laboratory Animals. Animal care 
was provided in accordance with the procedures outlined in the Guide for 
the Care and Use of Laboratory Animals (National Academies Press, 2011), 
and protocols were approved by UNC Chapel Hill or the University of 
Virginia Animal Care and Use Committee.
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Cell lines. All primary ECs were isolated from normal or tumor tis-
sue from 8- to 12-week-old mice. NECs and TECs from mammary tis-
sue were harvested from female mice. NECs and TECs from lungs were 
harvested from both male and female mice. Cells were cultured in 1 g/l 
D-glucose DMEM (LG-DMEM) with 10% FBS, 10% NuSerum IV, 10
ng/ml VEGF, 5 ng/ml bFGF, and 100 mg/l porcine heparin (referred to 
here as EC media). E0771 mammary tumor cells were from CH3 Bio-
Systems and were cultured in 4.5 g/l D-glucose DMEM (HG-DMEM)
and 10% FBS. Cells were maintained at 37°C in 5% CO2 plus 20% O2.
Mammary tumor studies in mice. Tgfbr2iECKO mice, control mice 
(Tgfbr2fl/fl), C57BL/6 mice, and PAI-1–KO mice were used in the mam-
mary tumor studies. E0771 murine mammary tumor cells were sus-
pended in HBSS at a density of 1.0 × 107 cells/ml, and 100 μl cell sus-
pension was orthotopically injected into the mammary fat pads of 8- to 
10-week-old mice. Tumors were harvested when they reached 1–2 cm3 
in size. Tumor measurements began when tumors were first palpable 
after injection (usually within 7 to 9 days).
Lung tumor induction in mice. LSL-KRASG12D/+ p53fl/fl Lkb1fl/fl mice were 
anesthetized and then positioned such that their airways were open and 
unobstructed by their tongue. Once the airway was clear, 37.5 μl Adeno- 
Cre virus (5 × 106 PFU/ mouse) was added dropwise into the airway of 
each mouse. The viral inoculation with 37.5 μl Adeno-Cre was performed 
twice. Tumors were allowed to grow for 4 weeks before the mice were sac-
rificed and the tumors harvested. Mice were weighed every 3 to 5 days.
Nanoparticle treatment of mice. Nanoparticle treatment began on 
the same day as tumor injections in mammary fat pads. Mice were treat-
ed 3 times per week intravenously at 1.5 mg/kg. All mice were treated 9 
times with nanoparticles except for PAI-1–KO mice, which were treated 
12 times because of the longer lag period for tumor establishment.
scRNA-Seq. A total of 3 mice were used. EO771 tumors were injected (1 
× 106 total cells) on one side of the mice (orthotopically in the mammary fat 
pad), and normal mammary glands were harvested from the other side. To 
obtain a sufficient number of ECs for sequencing, all samples were pooled 
prior to sorting. FACS-isolated NECs or TECs were counted and subject-
ed to 10× preparation and medium output sequencing on the NextSeq 
500 (Illumina) with an expected yield of 150,000,000 reads. Raw data 
were processed according to the manufacturer’s guidelines using the 10× 
Genomics Cell Ranger toolkit to create FASTQ files. Reads were aligned 
with STAR against the mm10 genome. Filtered gene-barcode matrices 
were imported into R using the Seurat package, keeping all genes expressed 
in at least 5 cells and all cells with at least 200 detectable expressed genes. 
We used a global scaling normalization that normalizes gene expression 
measurements for each cell by the total expression and log-transforms 
the result, followed by identification of highly variable genes to use for 
downstream analyses. Furthermore, we used the canonical correlation 
analysis–based (CCA-based) approach to “align” the data sets such that 
gene expression and differential expression could be analyzed without 
confounding batch effects. The raw data can be accessed on the NCBI’s 
Gene Expression Omnibus (GEO) database (GEO GSE118904).
Statistics. For tumor volumes and weights, the level of signifi-
cance was determined using ANOVA, Sidek’s multiple comparisons 
test (volumes), or a 2-tailed Student’s t test (weights). For branch 
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